Print Page     Close Window     

Investor Home

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizu...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$117.36

 3.67 (3.03%)

04/18/19  10:26 a.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy - April 9, 2019
Plan to pursue development as a monotherapy and in combination with BeiGene’s investigational anti-PD-1 antibody, tislel... Read More
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting - April 1, 2019
CAMBRIDGE, Mass. and BEIJING, China, April 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a c... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts
 

© 2016 BeiGene. All Rights Reserved.